Impact of Kras Codon Sub-types In A Phase Ii Second-line Trial In Kras-mutant Advanced Non-small Cell Lung Cancer (nsclc) of Selumetinib Plus Docetaxel Versus Docetaxel Alone

作者： J Vansteenkiste , G Mcwalter , J Walker , D Hodgson , B Dougherty

DOI:

关键词: